title: Compositional Magnetic Resonance Imaging Measures of Cartilage--Endpoints for Clinical Trials of Disease-modifying Osteoarthritis Drugs?
authors.affiliation: Professor of Radiology, Director, Quantitative Imaging Center, Boston University School of Medicine, Boston, Massachusetts; guermazi@bu.edu.
authors.forename: Ali
authors.initials: A
authors.lastname: Guermazi
authors.affiliation: Department of Radiology, Boston University School of Medicine, Boston, Massachusetts, USA, and Department of Radiology, Hospital do Coração and Teleimagem, São Paulo, Brazil;
authors.forename: Michel D
authors.initials: MD
authors.lastname: Crema
authors.affiliation: Department of Radiology, Boston University School of Medicine, Boston, Massachusetts, USA, and Department of Radiology, University of Erlangen, Erlangen, Germany.
authors.forename: Frank W
authors.initials: FW
authors.lastname: Roemer
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002358:Cartilage, Articular / Q000187:drug effects / Q000473:pathology*; D018450:Disease Progression; D042241:Early Diagnosis; D005260:Female; D005682:Gadolinium; D006801:Humans; D021621:Imaging, Three-Dimensional; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000473:pathology*; D011379:Prognosis; D011856:Radiographic Image Enhancement; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D005682:Gadolinium